MedPath

Sangamo Therapeutics Plans Accelerated Approval Pathway for Fabry Disease Gene Therapy

• Sangamo Therapeutics is pursuing accelerated approval from the FDA for its Fabry disease gene therapy, potentially expediting its path to market. • The FDA might allow Sangamo to use long-term data from its existing trial as a follow-up, foregoing the need for a separate confirmatory study. • Sangamo aims to use eGFR slope at 52 weeks across all patients from its Phase 1/2 study as the surrogate endpoint for approval. • Despite recent financial struggles, Sangamo's CEO believes this accelerated approval pathway will enhance partnership opportunities and shareholder value.

Sangamo Therapeutics is set to pursue an accelerated approval pathway from the FDA for its gene therapy targeting Fabry disease. This decision could significantly expedite the therapy's availability to patients.

FDA's Openness to Accelerated Approvals

The FDA has recently signaled a greater willingness to consider accelerated approvals, particularly for rare diseases and cell and gene therapies. Sangamo CEO Sandy Macrae noted that the FDA has not requested additional data beyond what has already been submitted, suggesting that longer-term data from the ongoing trial may suffice as a confirmatory measure. According to Macrae, the FDA might request the continuation of the trial to gather two-year data from all participants, but this has not been explicitly required.

Implications of No Confirmatory Trial

One potential consequence of forgoing a separate confirmatory trial is that the accelerated approval may not convert to a full approval. This could impact insurance coverage and the drug's pricing. However, Peter Marks, director of the FDA's Center for Biologics Evaluation and Research (CBER), has expressed his desire for accelerated approval to "be the norm" for gene therapies, even with biomarkers that are not yet fully qualified.

Clinical Data and Surrogate Endpoint

Sangamo intends to leverage data from its Phase 1/2 study for the accelerated approval application, utilizing the estimated glomerular filtration rate (eGFR) slope at 52 weeks across all patients as the surrogate endpoint. This dataset will include one-year data from all 32 patients in the study and two-year results from 19 patients, according to Macrae.

Company Challenges and Financial Outlook

Sangamo has faced financial headwinds, with its share price declining significantly from its 2020 peak. The company has undergone multiple restructurings and workforce reductions. However, Macrae stated that the decision to pursue accelerated approval was not driven by financial concerns. Sangamo is actively engaged in late-stage partnership discussions to secure non-dilutive funding, which the CEO believes will be bolstered by this recent development. In August, Sangamo partnered with Genentech on an epigenetic Alzheimer's therapy program, receiving $50 million upfront with potential milestone payments of $1.9 billion.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

uniQure Receives FDA Nod for Accelerated Approval Pathway for Huntington's Disease Gene Therapy

uniQure secured FDA agreement to pursue accelerated approval for its Huntington's disease gene therapy, potentially expediting treatment availability.
The FDA's decision reflects a more flexible approach to genetic medicines for severe rare diseases under Peter Marks.

FDA Grants Orphan Drug Designation to EXG110 Gene Therapy for Fabry Disease

The FDA has granted orphan drug designation to EXG110, a novel gene therapy developed by Exegenesis Bio for Fabry disease.
EXG110 is designed as a one-time treatment to deliver a genetic payload directly to liver and heart cells, potentially improving efficacy and safety.

Sangamo's ST-503 Receives FDA Clearance for iSFN Clinical Trials

Sangamo Therapeutics' ST-503, an epigenetic regulator for chronic neuropathic pain in idiopathic small fiber neuropathy (iSFN), has received FDA clearance for its IND application.
A Phase 1/2 study is planned for mid-2025 to evaluate the safety and efficacy of a one-time intrathecal treatment using AAV vector technology targeting the SCN9A gene.

Sangamo Therapeutics' Fabry Disease Candidate ST-920 Gains Accelerated Approval Pathway

Sangamo Therapeutics' shares surged after the FDA agreed to a regulatory pathway for accelerated approval of isaralgagene civaparvovec (ST-920) for Fabry disease.
The FDA will consider data from the Phase I/II STAAR trial, using the rate of decline in eGFR at 52 weeks as the primary basis for approval.

Sangamo's Fabry Disease Gene Therapy ST-920 Poised for Accelerated FDA Approval

Sangamo Therapeutics' ST-920 (isaralgagene civaparvovec) gene therapy for Fabry disease may secure accelerated FDA approval based on Phase 1/2 data, potentially expediting market entry.
The FDA has indicated that data from the ongoing STAAR trial, particularly the eGFR slope at 52 weeks, could serve as the primary basis for ST-920's accelerated approval.

Sangamo's Fabry Disease Gene Therapy ST-920 Receives Accelerated Approval Pathway from FDA

Sangamo Therapeutics' ST-920, a gene therapy for Fabry disease, gains FDA agreement for accelerated approval based on Phase 1/2 STAAR study data.
The FDA will consider eGFR slope at 52 weeks as the primary endpoint for accelerated approval, potentially expediting the BLA submission to the second half of 2025.

FDA Grants Rare Pediatric Disease and Orphan Drug Designations to Six Gene Therapies

The FDA has granted Rare Pediatric Disease (RPD) and Orphan Drug Designations (ODD) to six investigational gene therapies developed under the Accelerating Medicines Partnership (AMP) Bespoke Gene Therapy Consortium (BGTC).
These designations aim to incentivize the development of gene therapies for rare diseases affecting children, offering financial benefits such as Priority Review Vouchers and tax credits.

ARCA biopharma's Gencaro Receives FDA Fast Track Designation for Genotype-Defined Heart Failure

ARCA biopharma's Gencaro, a beta-blocker and vasodilator, has received FDA Fast Track designation for reducing cardiovascular mortality and hospitalizations in heart failure patients.
The company plans to submit a study protocol under the FDA's Special Protocol Assessment process for a clinical trial involving 3,000 chronic heart failure patients with a specific genotype.

FDA Rejects Regeneron's Accelerated Approval Applications Due to Lack of Confirmatory Studies

The FDA has rejected two accelerated approval applications from Regeneron Pharmaceuticals due to the absence of ongoing confirmatory studies.
This decision signals the FDA's intent to utilize its enhanced authority, granted in 2022, to ensure timely validation of drug efficacy.

FDA Grants Fast Track Designation to Panitumumab for Metastatic Colorectal Cancer Treatment

Amgen and Abgenix announced that the FDA has granted fast track designation to panitumumab, an experimental fully human monoclonal antibody, for treating metastatic colorectal cancer in patients who have failed standard chemotherapy. This designation aims to expedite the review process, potentially bringing a new treatment option to patients sooner.

Reference News

[1]
Sangamo to seek accelerated approval for Fabry gene therapy
endpts.com · Oct 23, 2024

Sangamo Therapeutics plans to seek accelerated FDA approval for its Fabry disease gene therapy, leveraging existing tria...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy